Daniel J. Rubin MD, MSc, FACE
Professor of Medicine; Director of Clinical Research; Deputy Chief, Section of Endocrinology, Diabetes, and Metabolism, Lewis Katz School of Medicine at Temple University; Chair, Glycemic Control Taskforce, Temple University Hospital, Philadelphia, PennsylvaniaDr. Rubin is Professor of Medicine in the Section of Endocrinology, Diabetes, and Metabolism at the Lewis Katz School of Medicine at Temple University and a Fellow of the American College of Endocrinology. He earned a Master of Science in Epidemiology with a concentration in Biostatistics at the Boston University School of Public Health. At Temple University Hospital, he serves as Chair of the Glycemic Control Taskforce. His research focuses on inpatient diabetes management and hospital readmissions among patients with diabetes. He is currently funded by an NIH/NIDDK K23 Award on predicting and preventing readmissions among diabetes patients.
Disclosures
Financial disclosures: Dr. Rubin has received research grants from AstraZeneca and Boehringer Ingelheim in the past 12 months. (07/22/17)Recent Contributions to PracticeUpdate:
- Associations Between Postdischarge Care and Cognitive Impairment–Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes
- Hospitalization Trends and Inpatient Mortality in Hyperosmolar Hyperglycemic State
- Glycemic Control, Sepsis Risk, and Mortality in Type 2 Diabetes
- In-Hospital Interventions and Reduced Length of Hospital Stay and Readmission of T2D Patients
- Racial and Ethnic Differences in 30-Day Hospital Readmissions Among Adults With Diabetes
- Association of Glucose Concentrations at Hospital Discharge With Readmissions and Mortality
- Readmission Rates in Patients With vs Without Diabetes Mellitus at an Urban Teaching Hospital
- Hospital Readmissions for Diabetes and the Impact of Hypo- and Hyperglycemic Events